Filed: May 10, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD MYLAN PHARMACEUTICALS INC., ACTAVIS BORATORIES FL, INC., AMNEAL PHARMACEUTICALS LLC

LABORATORIES FL, INC., AMNEAL PHARMACEUTICALS LLC,
AMNEAL PHARMACEUTICALS OF NEW YORK, LLC, DR. REDDY'S
LABORATORIES, INC., DR. REDDY'S LABORATORIES, LTD.,
SUN PHARMACEUTICALS INDUSTRIES, LTD.,
SUN PHARMACEUTICALS INDUSTRIES, INC.,
TEVA PHARMACEUTICALS USA, INC., WEST-WARD
PHARMACEUTICAL CORP., and HIKMA PHARMACEUTICALS, LLC,

Petitioners,

v.

JANSSEN ONCOLOGY, INC.,

Patent Owner.

Case IPR2016-01332¹ Patent 8,822,438 B2

PETITIONERS' OPPOSITION TO PATENT OWNER'S MOTION TO EXCLUDE

¹ Case IPR2017-00853 has been joined with this proceeding.



TABLE OF CONTENTS


			PAGE
I.	INTRODUCTION		
II.	THE BOARD SHOULD CONSIDER ALL OF PETITIONERS' COMMERCIAL SUCCESS EVIDENCE		3
III.	SUB	BOARD SHOULD CONSIDER THE FULL RECORD OF SMITTED EVIDENCE, ALL OF WHICH IS RELEVANT AND PORTS PETITIONERS' OBVIOUSNESS POSITIONS	6
	A.	Janssen Misrepresents That Certain Exhibits Are Not Discussed In The Petition Or Reply Brief	7
	В.	The Full Record Of Evidence Is Relevant, Including Evidence That Is Not Specifically Referred To By Pin Cite In The Briefing	7
IV.	THE BOARD SHOULD CONSIDER THE EXHIBITS OBJECTED TO DUE TO LACK OF AUTHENTICITY AND HEARSAY		11
V.	CONCLUSION		13



TABLE OF AUTHORITIES

CASES

Activision Blizzard, Inc. v. Acceleration Bay, LLC,	
IPR2015-01953, 2017 WL 1418497 (Patent Tr. & App. Bd. Mar. 23, 2017)	Q
BTG Int'l Ltd. v. Actavis Labs. FL, Inc., No. 2:15-cv-05909 (D.N.J. Jan. 30, 2017), ECF No. 274	13
	13
Meadwestvaco Packaging Sys., LLC Requester I v. Patent of C. Brown Lingamfelter,	
No. 2011-000001, 2011 WL 901354 (B.P.A.I. Mar. 14, 2011)	4
Nestle Healthcare Nutrition, Inc. v. Steuben Foods, Inc.,	
IPR2015-00249, 2016 WL 4366980 (P.T.A.B. June 2, 2016)	12
STATUTES	
35 U.S.C. § 311	4
35 U.S.C. § 311(b)	3, 5
OTHER AUTHORITIES	
Fed. R. Evid. 401, 402	10
Fed. R. Evid. 703	12
Fed. R. Evid. 801(c)	11
Fed. R. Evid. 801(d)(2)	12, 13
Fed. R. Evid. 803(6)	12, 13
Fed. R. Evid. 803(17)	12



I. INTRODUCTION

The patent at issue (U.S. Patent No. 8,822,438, or the '438 patent) relates to the administration of abiraterone acetate and prednisone to treat metastatic castration-resistant prostate cancer ("mCRPC"). Abiraterone acetate and prednisone have both been in the prior art since at least the mid-1990s, and both were known to be useful agents in prostate cancer treatment. Janssen now seeks to uphold a patent on the combination of these two agents, arguing that a skilled artisan would not have been motivated to use prednisone—commonly coadministered with other anti-cancer agents—with abiraterone acetate. The prior art provided ample motivation to combine these drugs. Indeed, during prosecution of the '438 patent, the Examiner found that the claimed method was prima facie obvious over the prior art and allowed the patent to issue solely on the basis of Janssen's commercial success arguments. Janssen now moves to exclude evidence that reinforces Petitioners' obviousness positions. The motion has no merit.

In its Motion, Janssen seeks to exclude three categories of evidence: (1) expert declarations and exhibits on the subject of commercial success; (2) sections of Petitioners' expert declarations and exhibits that Patent Owner argues are irrelevant; and (3) certain exhibits Janssen claims are not authentic or constitute inadmissible hearsay.



None of this evidence should be excluded. In order to evade Petitioners' strong commercial success rebuttal, Janssen misconstrues the aim of Petitioners' commercial success arguments by characterizing those arguments as a "ground" for invalidating the '438 patent. Not so. Petitioners' arguments simply set forth why the patent examiner possessed an incomplete picture of commercial success when allowing the '438 patent to issue solely on that basis. Petitioners thus set forth a fulsome commercial success analysis to establish why this secondary indicia does not overcome the obviousness of the '438 patent.

Janssen also asserts that certain exhibits and paragraphs of Petitioners' expert declarations are irrelevant simply because they are not explicitly cited within Petitioners' Reply or Petition. The record is not limited to the Petitioners' Petition and Reply Brief. The objected-to exhibits are discussed in Petitioners' expert declarations, and the objected-to declaration paragraphs provide highly relevant information and detail supporting Petitioners' obviousness arguments.

Finally, Janssen asserts that numerous exhibits lack authenticity, failing to even mention Petitioners' supplemental evidence. Janssen also claims three exhibits constitute hearsay, only providing reasoning for two of the three exhibits. All three exhibits do not constitute inadmissible hearsay and should not be excluded.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

